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Abstract
MenAfriVac is a new conjugate vaccine against Neisseria meningitidis serogroup A developed for the African ‘‘meningitis
belt’’. In Niger, the first two phases of the MenAfriVac introduction campaign were conducted targeting 3,135,942
individuals aged 1 to 29 years in the regions of Tillabe ´ri, Niamey, and Dosso, in September and December 2010. We
evaluated the campaign and determined which sub-populations or areas had low levels of vaccination coverage in the
regions of Tillabe ´ri and Niamey. After Phase I, conducted in the Filingue ´ district, we estimated coverage using a 30615
cluster-sampling survey and nested lot quality assurance (LQA) analysis in the clustered samples to identify which
subpopulations (defined by age 1–14/15–29 and sex) had unacceptable vaccination coverage (,70%). After Phase II, we
used Clustered Lot Quality Assurance Sampling (CLQAS) to assess if any of eight districts in Niamey and Tillabe ´ri had
unacceptable vaccination coverage (,75%) and estimated overall coverage. Estimated vaccination coverage was 77.4%
(95%CI: 84.6–70.2) as documented by vaccination cards and 85.5% (95% CI: 79.7–91.2) considering verbal history of
vaccination for Phase I; 81.5% (95%CI: 86.1–77.0) by card and 93.4% (95% CI: 91.0–95.9) by verbal history for Phase II. Based
on vaccination cards, in Filingue ´, we identified both the male and female adult (age 15–29) subpopulations as not reaching
70% coverage; and we identified three (one in Tillabe ´ri and two in Niamey) out of eight districts as not reaching 75%
coverage confirmed by card. Combined use of LQA and cluster sampling was useful to estimate vaccination coverage and to
identify pockets with unacceptable levels of coverage (adult population and three districts). Although overall vaccination
coverage was satisfactory, we recommend continuing vaccination in the areas or sub-populations with low coverage and
reinforcing the social mobilization of the adult population.
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Introduction
The African ‘‘meningitis belt’’ is an area that stretches from
Senegal to Ethiopia, where major epidemics of meningococcal
meningitis regularly occur [1]. Neisseria meningitidis serogroup A is
the primary cause of meningitis epidemics in the meningitis belt
[2]. The human toll from these epidemics is enormous. In the
1996–1997 epidemics, more than 250,000 cases and 25,000 deaths
were reported [3]. During the 2009 epidemic season, 14 countries
reported a total of 78,416 cases, including 4,055 deaths. After
Nigeria, Niger was the second most affected country [2].
The Meningitis Vaccine Project (MVP) was created by the
World Health Organization (WHO) and the Program for
Appropriate Technology in Health (PATH) with the goal of
eliminating meningococcal epidemics in Africa through the
development, licensure, introduction, and widespread use of
conjugate meningococcal vaccines [4]. Thanks to a grant from
the Bill & Melinda Gates Foundation, an affordable (less than US$
0.50 per dose), effective, and long-lasting meningococcal A
conjugate vaccine (MenAfriVac) was developed by the MVP and
manufactured by the Serum Institute of India [5]. MenAfriVac
was pre-qualified by WHO in June 2010 [6] and introduced in
multiple phases in Burkina Faso, Mali and Niger, to optimize the
preparation for its widespread use in Africa [6,7]. During the first
phase (Phase I) of the introduction campaigns, pregnant or
lactating women were not recommended to receive the vaccine
due to limited data on vaccine safety in these populations [7]. This
recommendation was revised for the following phases since the
Global Advisory Committee on Vaccine Safety (GACVS)
considered that benefit of meningitis vaccination outweighed the
theoretical risk of adverse events following immunization (AEFI)
for pregnant or breastfeeding women (WHO Technical Note 22/
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gitis belt: use of vaccine in pregnant and lactating women).
In Niger, the Phase I campaign was conducted in the district of
Filingue ´ in the region of Tillabe ´ri in September 2010. The second
phase of the introduction (Phase II) was conducted in the regions
of Niamey, Tillabe ´ri, and Dosso in December 2010.
The WHO Expanded Programme on Immunization (EPI)
recommends two methods for the evaluation of vaccination
campaigns: cluster sampling to obtain estimates of vaccination
coverage in a defined area [8] and lot quality assurance sampling
(LQAS) to identify possible pockets of low coverage [9,10]. After
each of the two phases, we combined cluster sampling and LQAS
to evaluate vaccination coverage and to determine whether some
sub-populations or districts had unacceptably low levels of
coverage in order to assist future vaccination strategies.
Methods
Ethics Statement
The study protocol was ratified by the National Campaign
Organization Committee chaired by the Ministry of Health in
Niger. Ethical approval for the survey was granted locally by the
Ministry of Health of Niger as part of the standard procedure to
evaluate national immunization campaigns. The International
Vaccine Institute’s Institutional Review Board also reviewed and
waived the need for approval.
Phased Vaccination Campaigns
The campaigns targeted individuals between 1 and 29 years of
age, representing approximately 70% of the total population. The
Ministry of Health organized the introduction campaigns adopting
fixed, outreach, and mobile strategies according to local
characteristics of the vaccinating areas. Each vaccinated individual
received a vaccination card and each vaccine dose was recorded in
a tally sheet to count how many doses were administered by age
group and per day. In addition, social mobilization activities about
the benefit of this new vaccine were undertaken before and during
the campaigns.
Phase I was conducted in the district of Filingue ´ in the region of
Tillabe ´ri from 21 to 27 September with the objective of
vaccinating at least 90% of the target population. After Phase I,
administrative coverage was 85%, thus the decision was made to
conduct mop-up activities from 7 to 9 October 2010. Phase II was
conducted in the regions of Niamey (three districts predominantly
urban), Tillabe ´ri (five districts predominantly rural), and Dosso
(two districts predominantly rural) from 7 to 16 December 2010
with the same objective.
Cluster Sampling Survey with Nested Lot Quality
Assurance Analysis in Four Sub-Populations after Phase I
After Phase I, we conducted a cluster sampling survey in the
target district of Filingue ´ between 24 October and 2 November
2010. The study population was represented by the 392,221
individuals aged 1–29 years reported living in Filingue ´ (National
Population Census 2001, Niger Institute of National Statistics). We
calculated a sample size of 450 subjects divided into 30 clusters of
15 (confidence interval: 95%; precision: 5%; expected coverage:
85%; design effect: 2) [11].
We nested the lot quality assurance (LQA) methodology in the
cluster sample to assess if each of four sub-populations, defined as
lots (Lot 1: boys aged 1–14 years; Lot 2: girls aged 1–14 years; Lot
3: men aged 15–29 years; Lot 4: women aged 15–29) had reached
a minimum acceptable level of 70% vaccination coverage. In
accordance with LQA methods [12,13], we set the upper coverage
threshold (UT) to 90% and the lower coverage threshold (LT) to
70%, yielding a decision value (d) of 5 in a sample (N) of 30, with
alpha (the probability of classifying a lot as acceptable with
unacceptable coverage) at 8% and beta (the probability of
classifying a lot with acceptable coverage as unacceptable) at
7%. Operationally, this meant that if 5 or less unvaccinated
individuals were found in the sample of 30, then the lot would be
classified as acceptable (i.e. coverage is equal or above 70%); if 6 or
more unvaccinated were found then it would be classified as
unacceptable.
In each of the 30 clusters, we considered the first individual
sampled per lot for the nested LQA analysis. In case not all lots
were represented in the cluster sample of 15 individuals, surveyors
were instructed to continue selecting individuals until all four lots
were represented. If additional samples were needed for the LQA
analysis, they would not be included in the estimation of
vaccination coverage by cluster sampling, since the probability
of selection would have been different.
Clustered Lot Quality Assurance Sampling Survey after
Phase II
After Phase II, we conducted a series of clustered lot quality
assurance sampling (CLQAS) surveys at district level in the
regions of Niamey (Districts: I, II, and III) and Tillabe ´ri (Districts:
Kollo, Say, Ouallam, Te ´ra, and Tillabe ´ri) between 19 and 28
December 2010. The study population was represented by the
2,136,287 individuals aged 1 to 29 years, residing in the two
regions (excluding the district of Filingue ´ already covered in
Phase I).
According to the CLQAS methodology, we defined each
district as a lot and designed different sampling plans with
N=100 divided in 10 clusters (k) of 10 individuals (n) and
calculated alpha and beta based on different coverage thresholds
assuming that coverage in the clusters (n=10) would not vary
more than 0.1 standard deviations from the coverage in the lot
(N=100) [14]. We eventually choose the plan with UT=90%,
LT=75%, and d=16 since it provided the lowest error levels:
alpha#4% and beta#8%. The decision rule was as follows: if up
to 16 unvaccinated individuals were found in each lot (district),
then the lot was classified as acceptable with at least 75%
vaccination coverage; if 17 or more unvaccinated were found
then it was classified as unacceptable without achieving 75% of
coverage.
We aggregated the data from the lots by adjusting them for the
population size and for the size of the household (total number of
target individuals living in the selected household) to estimate
coverage in each of the two regions (excluding Filingue ´). In the
region of Niamey, the sample of 300 individuals (3610610) would
be sufficient to achieve an accuracy of 5% with a 95% confidence
interval (CI), if we assumed 90% vaccination coverage and
deff=2. In the region of Tillabe ´ri, the sample of 500 (5610610)
would be sufficient to achieve an accuracy of 5% with a 95% CI, if
we assumed 80%vaccination coverage and deff=2.
Sampling Procedure
The clusters (villages) were selected in each district using
probability proportionate to population size (PPS) as described in
two-stage cluster sampling methods [11] . We selected the first
household in each cluster according to geographic random
sampling: we drafted a map of the locality, divided it into smaller
sectors according to existing divisions (streets, rivers, etc), and
selected one sector according to simple random sampling (SRS).
In each household, we listed all the residents aged 1–29 and
selected one with SRS for the interview. If the selected individual
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selected participant was under 12 years of age, an older member of
the household was invited to answer the questionnaire for that
child. If only children under 12 years were present in the house,
we did not conduct the interview and moved to the subsequent
household instead.
Outcome Measures and Definitions
We defined ‘‘vaccinated’’ as a person aged between 1–29 years
who had received the MenAfriVac during the campaigns.
We measured vaccination coverage on two levels: based on the
exclusive availability of the hand-held vaccination card (card
only) and considering also if the individuals (or their care-takers)
were verbally reporting as having been vaccinated (card+history).
During the Phase I evaluation we collected information on the
awareness about the campaign and on reasons for non-
vaccination using multiple choice questions. During the Phase
II evaluation we additionally collected information on the
awareness about the hypothesized ten years length of protection
of the vaccine. We used a structured pre-tested questionnaire for
data collection.
Statistical Analysis
Data entry and cleaning were conducted in Excel 2007
(Microsoft Corporation).
Analyses were conducted with STATA version 11 (STATA
Corp). We used the ‘‘svyset’’ command for complex survey
designs, using the population size of the districts and the number of
eligible individuals living in the households to define the survey
weights in order to account for differences in probability of
selection. We obtained coverage estimates with 95% CI using the
‘‘svy:proportion’’ command.
We compared survey results with reported administrative
coverage (the number of vaccine doses administered divided by
the number of persons in the target population) and the
coverage estimates from the region of Niamey (a predominantly
urban region) with the estimates from Tillabe ´ri (predominantly
rural).
We combined the results from Phase I and Phase II to obtain an
overall estimation of MenAfriVac vaccination coverage for the
regions of Niamey and Tillabe ´ri, using the formula for aggregating
the results of multiple surveys conducted in different strata [8,15].
Results
Phase I
We conducted 450 interviews in Filingue ´. Female respondents
were 230 (51.1%). Estimated vaccination coverage was 77.4 (95%
CI 70.2–84.6) by card only and 85.5% (95% CI: 79.7–91.2) by
card or verbal history (Table 1). The majority (90.5%) of the 380
individuals who claimed to be vaccinated showed the vaccination
card during the interview. Reasons for non-vaccination are
presented in Table 2.
The nested LQA analysis was completed in the four lots using
the cluster survey data. The sample of 450 was sufficient to obtain
the 120 sampling units (3064) without recruitment of additional
individuals. Based on the presence of the vaccination card, we
classified the two sub-populations of 1–14 years of age as
acceptable with vaccination coverage above 70% and the two of
15–29 years as unacceptable (Table 3).
Phase II
Between 19 and 28 December 2010, we conducted 800
interviews in the regions of Niamey and Tillabe ´ri (excluding
Filingue ´). The majority (472; 59.2%) of respondents were female.
Estimated vaccination coverage was 81.5% (95%CI: 77.0–86.1) by
card only and 93.4% (95% CI: 91.0–95.9) by card or verbal
history (Table 1). The majority (87.3%) of the 747 vaccinated
individuals showed the vaccination card during the interview. Two
individuals reported being vaccinated elsewhere (one in Burkina
Faso and one in Filingue ´) but did not have the vaccination card;
they were considered vaccinated as confirmed by verbal history in
the analysis.
Seventy-eight percent (95%CI: 71.2–84.7) of respondents were
aware that the campaign was conducted with a new vaccine
against meningitis and 70.5% (95%CI: 63.0–78.0) of them were
aware that its duration of protection is assumed to be up to ten
years. Reasons for non-vaccination are presented in Table 2.
The CLQAS surveys were completed in the eight districts (lots).
Based on card-confirmed vaccination status, five districts were
classified as acceptable with vaccination coverage equal to or
above 75%; while three were classified as unacceptable with
coverage below 75% despite presenting administrative coverage
above 100%. Allowing also for verbal confirmation, all districts
were accepted (Table 4).
Table 1. MenAfriVac vaccination coverage in persons aged 1–29 years for the two phases presented by administrative coverage
and coverage survey results, Niger, October–December 2010.
Survey
Card Only Card+History
Phase Population
Administrative
Coverage Sampled Vaccinated
Estimated Coverage
[95%CI] Vaccinated
Estimated Coverage
[95%CI]
I Total 90.7% 450 340 77.4% [70.2–84.6] 380 85.5% [79.7–91.2]
II Total 103.6% 800 647 81.5% [77.0–86.1] 747 93.4% [91.0–95.9]
Niamey 107.1% 300 221 75.7% [65.9–85.4] 276 92.7% [88.5–96.8]
Tillabe ´ri 102.0% 500 426 84.3% [79.3–89.3] 471 93.8% [90.7–96.9]
1–14 101.9% 563 465 83.4% [78.8–88.0] 539 96.0% [94.0–98.1]
15–29 107.0% 237 182 77.0% [69.5–84.5] 208 87.2% [81.3–93.0]
Male - 328 266 83.2% [77.8–88.6] 311 95.8% [92.9–98.7]
Female - 472 381 80.4% [74.8–86.0] 436 91.8% [88.7–94.9]
doi:10.1371/journal.pone.0029116.t001
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After the two phases, the overall estimated vaccination coverage
against meningococcal A in Tillabe ´ri and Niamey was 80.9%
(95% CI: 74.4–87.4) documented by card only and 92.2% (95%
CI: 87.0–97.4) considering card or verbal history of vaccination;
87.6% (987/1127) of the people considered vaccinated showed the
vaccination card.
Discussion
We evaluated the first two phases of the MenAfriVac
introduction campaign in the regions of Tillabe ´ri and Niamey in
Niger using a combination of cluster-sampling and LQAS
techniques. Overall vaccination coverage was 81% based on the
availability of vaccination cards; 92% considering also verbal
report of vaccination as a reliable source of information. After
Phase I, we identified two sub-populations with unacceptably low
coverage (,70%): males and females aged between 15–29 years
considering both vaccination cards only and verbal history of
vaccination. After Phase II, we identified three districts out of eight
with unacceptably low vaccination coverage (,75%) because of
the absence of vaccination cards; relying on verbal confirmation of
vaccination status, we classified all three as with acceptable
coverage. If this new conjugate vaccine against Meningococcus A
is as effective in preventing meningococcus carriage as the
Meningococcal C conjugate vaccine, the level of coverage
achieved would be sufficient to provide herd immunity in the
population, even with the most conservative assumption that
74.4% (lower confidence limit for the overall coverage estimate
based on card retention) of people aged 1–29 (70% of the general
population) were vaccinated, [16–19].
The fact that 88% of individuals who claimed to be vaccinated
were able to show the card suggests that the population
understood its importance. However, towards the end of the
Phase II campaign, some districts reported shortage of vaccination
cards, which could explain why we rejected three districts based on
card confirmed vaccination status but accepted them considering
verbal vaccination status.
After Phase I, the most common reason for non-vaccination was
being pregnant or breastfeeding. This is not surprising since, at
that time, pregnant or lactating women were not recommended to
receive the vaccine. Being absent was the second most common
reason for Phase I and the first for Phase II. This finding was
expected for Phase I since the campaign was conducted only in
one district in a shorter period of time, so individuals who were
commuting to or working in outer areas of the district would have
not been able to receive the vaccine; it is more surprising for Phase
II since the campaign covered a much larger area than Phase I
Table 2. Reasons for non-vaccination in the individuals reportedly not vaccinated during Phase I (n=70) and Phase II (n=53) of
the MenAfriVac introduction campaign, Niamey and Tillabe ´ri, Niger, September–December 2010.
Phase I Phase II
Reason for non-vaccination Result (%) Result (%)
Being pregnant or breastfeeding 21 (30.0) 0 (0)
Absent during the time of vaccination 20 (28.6) 13 (24.5)
Vaccinator was absent when they presented for vaccination 16 (22.9) 8 (15.1)
Lack of information about the campaign 4 (5.7) 7 (9.4)
Sick during the time of vaccination 4 (5.7) 8 (15.1)
Vaccine was out of supply 0 (0) 3 (5.7)
Refusal/Not interested in vaccination 3 (4.3) 9 (17.0)
No more cards available 1 (1.4) 0 (0)
Vaccination site too far 0 (0) 1 (1.9)
Time of vaccination not convenient 1 (1.4) 1 (1.9)
Other 0 (0) 3 (5.7)
Total 70 (100) 53 (100)
doi:10.1371/journal.pone.0029116.t002
Table 3. Vaccination coverage results in persons aged 1–29 years for Phase I of the first phase of the MenAfriVac introduction
campaign presented by administrative coverage and Lot Quality Assurance (LQA) analysis, Filingue, Niger, October 2010.
LQA Analysis (N=30)
Card Only Card + History
Age Group Administrative Coverage Lot Unvaccinated Decision Unvaccinated Decision
1–14 years 98.6% Males 1–14 years 5 Accepted 3 Accepted
Females 1–14 years 4 Accepted 2 Accepted
15–29 years 74.0% Males 15–29 years 10 Rejected 6 Rejected
Females 15–29 years 18 Rejected 16 Rejected
doi:10.1371/journal.pone.0029116.t003
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Sixteen unvaccinated individuals for Phase I and eight for Phase II
reported not being vaccinated because the vaccinators were absent
from their post, suggesting that there may have been program-
matic issues in organizing vaccination activities, especially for
Phase I. Overall twelve unvaccinated individuals refused the
vaccine, while eleven were not vaccinated as a result of insufficient
information. These results suggest communication to the popula-
tion should be reinforced.
The proportion of individuals who were aware that the
campaign was conducted with a new vaccine against meningitis
was much higher in Phase II than in Phase I, suggesting that the
social mobilization may have been more effective in Phase II in
terms of delivering messages regarding the vaccine.
Administrative coverage can be used to take operational
decisions following vaccination campaigns [20–22]. Levels of the
administrative coverage ranged from 91% to 113% in the nine
districts under evaluation. Coverage estimates were well below
post-campaign administrative coverage. This discrepancy can be
explained by two reasons: firstly, the denominator used to
calculate the administrative coverage may be out of date or
underestimated; secondly, it is possible that vaccines were
administered to individuals who are out of the target group (1–
29 years of age) or not included in the denominator (e.g. new
residents, migrant workers, nomadic population, etc.).
The cluster sampling method provides a coverage estimate
with 95% CI for the entire territory or population under study,
but it does not provide information on pockets of unvaccinated
individuals [23]. Depending on levels of expected coverage,
cluster sampling surveys would require sample sizes in the order
of hundreds individuals to obtain reliable estimates [11]. After
Phase I, to identify unvaccinated pockets, we decided not to
conduct cluster sampling surveys in sub-populations. Instead,
we nested the LQAS methodology in the cluster sampling
s u r v e ya n di d e n t i f i e dt h a tb o t ht h ef e m a l ea n dm a l ea d u l t
groups had low vaccination coverage. With regards to the
female adult group, this was not surprising, since pregnant or
breastfeeding women were not recommended to receive the
vaccine during Phase I. As for adult males, this population has
not been usually the target of vaccination campaigns, and may
have not been aware of the fact that the campaign was targeting
them too.
After Phase II, we wanted to verify whether each targeted
district had achieved at least 75% of coverage. We also intended to
test if coverage in Tillabe ´ri, which reported 102% of administra-
tive coverage, was lower than coverage in the region of Niamey,
which was reported as 107%. We applied the CLQAS
methodology and obtained results at multiple levels. We confirmed
that three districts (Niamey II, III, and Say), all with administrative
coverage levels above 100%, had not achieved 75% coverage by
card retention, showing that making operational decisions only
relying on administrative coverage has a high chance of missing
vulnerable populations in need. Second, we obtained coverage
estimates at regional and higher level, showing that the coverage
estimates (especially by verbal history) were not significantly
different between Tillabe ´ri and Niamey. Niamey, the capital city,
is encircled by Tillabe ´ri and has more residents or commuters than
registered, which is vice versa for Tillabe ´ri. Our result suggests that
administrative coverage might have been overestimated, especially
in the region of Niamey, where many individuals were not
included in the denominator even if they were actually vaccinated.
Nesting the LQA analysis in the cluster survey or aggregating
data from CLQAS allowed us to conduct the survey with greater
feasibility and to obtain more information than we would have
normally obtained from traditional cluster surveys. One previous
study has explored the applications of nesting LQAS in cluster
sampling to compare power and precision of different study
designs to assess the prevalence of acute malnutrition [24]. In our
case, we nested LQA in the cluster sample to assess vaccination
coverage at sub-population level rather than to compare the two
methods. CLQAS demonstrated to be an efficient methodology in
the context of Phase II, which covered vast areas of the country. As
expected, clustering sampling points in lots increased the feasibility
of the survey in the field [15,25], since the teams had to travel only
to ten locations per district.
This study was subject to a number of limitations. Firstly, since
we have instructed surveyors not to spend longer than reasonable
time until the interviewee found the vaccination card, it is possible
that we underestimated the proportion of card retention. Asking
for detailed information about the vaccination card (e.g. whether
the card was actually given or enquiring about the reasons why it
was not available) may have been a way to overcome this
limitation. We also conducted the surveys shortly after completion
of vaccination activities so to increase the likelihood of card
Table 4. Vaccination coverage results in persons aged 1–29 years for the second phase of the MenAfriVac introduction by
administrative methods and Clustered Lot Quality Assurance Sampling (CLQAS) survey, Niamey and Tillabe ´ri, Niger, December
2010.
CLQAS Survey (N=100)
Card Only Card + History
Region District/Lots Administrative Coverage Unvaccinated Decision Unvaccinated Decision
Niamey Niamey I 107.4% 16 Accepted 9 Accepted
Niamey II 106.3% 18 Rejected 5 Accepted
Niamey III 108.5% 19 Rejected 10 Accepted
Tillabe ´ri Tillabe ´ri 98.3% 6 Accepted 4 Accepted
Ouallam 100.6% 6 Accepted 5 Accepted
Kollo 97.9% 12 Accepted 8 Accepted
Say 112.8% 17 Rejected 9 Accepted
Te ´ra 102.2% 4 Accepted 3 Accepted
doi:10.1371/journal.pone.0029116.t004
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done after mop-up activities so it was impossible to guide further
vaccination activities in the district with the results of the
evaluation. Thirdly, in Phase II, more females were surveyed
than males, which may have biased the results if vaccination
coverage is associated with gender. We were not able to check this
association due to the small sample size in our survey. Lastly, if any
adult member of the household or the individual selected for the
survey were not reachable within a reasonable amount of time (e.g.
was not spending the night away) before the completion of the
cluster we instructed the surveyors to move to the subsequent
household. Although this is a common practice, it may have biased
the survey results in the sense that individuals present in the house
at daytime had better chances of being selected in the survey [15].
In conclusion, our results suggest that vaccine coverage was
satisfactory in Niamey and Tillabe ´ri, although a number of
unvaccinated individuals may exist, especially in the adult
population and some districts. Combined use of LQAS and
cluster sampling techniques allowed us to evaluate the campaigns
at macro- (regional) and micro- (subpopulation and district) levels
with greater timeliness and feasibility. These survey designs are
complementary, cluster sampling being most useful to estimate
coverage, LQAS or CLQAS to detect under-immunized pockets
in certain populations or areas.
Ideally independent evaluations should be conducted at the end
[26] or immediately after [25] the campaign to guide appropriate
mop-up actions in close contact with local health authorities.
Population estimates should be revised or updated in the country
to improve the quality of the micro-planning and allocation of
resources for future campaigns. In addition to enquiring about
reasons for non-vaccination, we recommend including questions to
investigate also the reasons for the absence of vaccination cards in
order to plan appropriate measures to increase card retention in
the population.
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